July 10, 2013
Yoshinari Takasaki, President of the Japan College of Rheumatology The new oral rheumatoid arthritis (RA) treatment Xeljanz (tofacitinib; Pfizer Japan) was added to the NHI price list on May 24. Xeljanz has attracted interest as an oral drug which may...read more